AU2004236263A1 - Compositions and methods for treatment of cryptococcosis - Google Patents

Description

WO 2004/099251 PCT/US2004/014276 COMPOSITIONS AND METHODS FOR TREATMENT OF CRYPTOCOCCOSIS TECHNICAL FIELD OF THE INVENTION 5 100011 The present invention relates to compositions and methods for treating or preventing Cryptococcus neoformans infection and conditions caused by such infection. The present invention relates to human antibodies that specifically bind to C. neoformans capsular glucuronoxylomannan (GXM) and nucleic acid molecules that encode the antibodies. The invention also relates to isolated heavy and light chain immunoglobulin 10 molecules of the human antibodies to C. neoformans GXM. The invention further relates to nucleic acid molecules that encode such heavy and light chain immunoglobulin molecules. The invention further comprises human antibodies to C. neoformans GXM that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to methods of detecting or monitoring C. neoformans 15 infection. The invention further relates to methods for making the antibodies in a non human animal and expressing the antibodies in cell lines including hybridomas and recombinant host cell systems. The invention also relates to kits and pharmaceutical compositions comprising the antibodies. The invention further relates to methods of treating or preventing C. neoformans infection and conditions caused by such infection by 20 administering to a patient compositions described herein. BACKGROUND OF THE INVENTION 10002] Cryptococcus neoformans is an important human pathogen and a major cause of morbidity and mortality in humans, especially those who are immunocompromised.

WO 2004/099251 PCT/US2004/014276 2 Despite the availability of antifungal agents active against C. neoformans, cryptococcosis is largely incurable in immunocompromised patients because the organism cannot be fully eradicated. Thus, treatment may require costly life-long anti-fungal prophylaxis or maintenance therapy to control the infection. 5 [00031 Several treatments are available to prevent recrudescent disease, including azole prophylaxis, which along with highly active antiretroviral therapy, has reduced the incidence of HIV-associated cryptococcosis in the developed world. However, cryptococcosis is an emerging problem in other immunocompromised patient populations and remains a major cause of meningoencephalitis in the developing world. Furthermore, 10 because of prolonged maintenance therapies with anti-fungal drugs the incidence of resistant strains is increasing. Accordingly, there is an urgent need for additional approaches for the prevention and treatment of cryptococcosis. BRIEF SUMMARY OF THE INVENTION 15 [00041 The present invention provides isolated human antibodies that specifically bind to C. neoformans capsular glucuronoxylomannan (GXM). In particular, the invention provides monoclonal antibodies G14F7E5, G15B4G5 and G19B9G7 which recognize C. neoformans GXM. Monoclonal antibody G15B4G5 effectively protects against C. neoformans challenge in passive immunizations. The invention further provides methods 20 for making the antibodies in non-human animals and by expression of the antibodies in cell lines including hybridomas and recombinant host cell systems. The invention also provides kits and pharmaceutical compositions comprising the antibodies. Moreover, the invention provides methods of treating or preventing C. neoformans infection and conditions caused by such infection by administering to a patient pharmaceutical 25 compositions described herein.

WO 2004/099251 PCT/US2004/014276 3 BRIEF DESCRIPTION OF THE DRAWINGS [00051 Figure 1 shows inhibition curves for G14F7E5, G15B4G5 and G19B9G7 by soluble GXM. Binding by ELISA is shown. Panel A shows inhibition of the binding of Mabs to 24067 by soluble SB4; Panel B shows inhibition of the binding of Mabs to 24067 5 by 24067; and Panel C shows inhibition of the binding of the Mabs to H99 by soluble SB4. Binding is represented by the absorbance (Abs) at 405 nm as shown on the y axis for concentration of the indicated Mab on the x axis. [00061 Figure 2 shows a passive immunization experiment with MAbs G14F7E5, G15B4G5 and G19B9G7. 10 Figure 3 is a table comparing a portion of the CDR1 and the CDR2 of monoclonal antibodies to C. neoformans GXM. Residues that are in bold and underlined are ones that are shared by murine and human XenoMouse@ mouse-derived monoclonal antibodies; residues in bold and italics are somatic mutations; residues in italics (not bolded) are residues that are similar among antibodies but in different positions; residues in lower case 15 are associated with diminished GXM binding. Hu- human; Ms - mouse. DETAILED DESCRIPTION OF THE INVENTION [0007] The present invention provides fully human antibodies or antigen-binding portions thereof that specifically bind to C. neoformans GXM. In some embodiments, the 20 fully human antibodies are monoclonal. Other embodiments include nucleic acid molecules comprising nucleotide sequences encoding all or part of the antibodies' heavy and light chains and polypeptides comprising the amino acid sequences encoded by such nucleotide sequences, and in particular sequences comprising the complementarity determining regions (CDRs). Antibodies having similar binding properties and antibodies 25 (or other antagonists) having similar functionality as antibodies disclosed herein are also provided. Hybridomas expressing such immunoglobulin molecules and monoclonal antibodies are also provided. [00081 Unless otherwise defined herein, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly 30 understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Generally, nomenclatures used in connection with, and techniques of, cell and tissue culture, molecular biology, immunology, microbiology, genetics and protein and nucleic WO 2004/099251 PCT/US2004/014276 4 acid chemistry and hybridization described herein are those well known and commonly used in the art. Unless otherwise indicated, the methods and techniques of the present invention are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and 5 discussed throughout the present specification. See, e.g., Sambrook et al. Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989) and Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates (1992), and Harlow and Lane Antibodies: A Laboratory Manual Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1990), which are 10 incorporated herein by reference. Enzymatic reactions and purification techniques are performed according to manufacturer's specifications, as commonly accomplished in the art or as described herein. The nomenclatures used in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and 15 commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients. [0009] The following terms are intended to have the following general meanings as they are used herein: [0010] "B lymphocytic cells or progeny thereof' refer to any cell descending from, or 20 destined for, the B lymphocytic lineage. Examples include, but are not limited to, all B lymphocytes in the B cell developmental pathway starting from the earliest B lymphocyte stem cells through memory B cells, plasma cells, and any hybridomas created in vitro. [0011] "Bispecific antibodies" are single antibodies that have affinities for two separate antigens. For example, a bispecific antibody might recognize C. neoformans GXM using 25 one combination of heavy and light chains and might recognize a leukocyte cell surface marker using a second combination of heavy and light chains attached to the first combination. See, e.g., McCormick et al., J Immunol. 158:3474-82 (1997). 10012] "Chimeric antibodies" are antibodies that have been altered from their original form to comprise amino acid sequences from another protein. Chimeric antibodies retain 30 at least a portion of the original antibody amino acid sequence, typically the portion comprising the antigen binding region (Fab). Examples of chimeric antibodies include, but are not limited to, bispecific antibodies and fusions with other non-immunoglobulin protein sequences.

WO 2004/099251 PCT/US2004/014276 5 [0013] "Cytokines" refer generally to signaling molecules of the immune system. Cytokines include, but are not limited to, interleukins (IL), transforming growth factors (TGF), tumor necrosis factors (TNF), lymphotoxins (LT), interferons, granulocyte macrophage colony stimulating factors (GM-CSF), macrophage CSF, granulocyte CSF, 5 and migration inhibition factors. [00141 "Derivatize" refers to the process of attaching a non-immunoglobulin agent to the immunoglobulin molecules. Examples of derivatizing agents include, but are not limited to, toxins, complement, antibiotics, peptides, polysaccharides, lipids, organic polymers, radiolabels, and inorganic compounds. 10 [0015] "Fusion proteins" refer to chimeric proteins comprising amino acid sequences of two or more different proteins. Typically, fusion proteins result from in vitro recombinatory techniques well known in the art. However, fusion proteins may result from in vivo crossover or other recombinatory events. [0016] The term "polypeptide fragment" as used herein refers to a polypeptide that has 15 an amino-terminal and/or carboxy-terminal deletion, but where the remaining amino acid sequence is identical to the corresponding positions in the naturally-occurring sequence. Fragments typically are at least 5, 6, 8 or 10 amino acids long, including, e.g., at least 14 amino acids long, at least 20 amino acids long, at least 50 amino acids long, and at least 70 amino acids long. 20 [0017] Fragments or analogs of antibodies or immunoglobulin molecules can be readily prepared by those of ordinary skill in the art following the teachings of this specification. Generally, amino- and carboxy-termini of fragments or analogs occur near boundaries of functional domains. Structural and functional domains can be identified by comparison of the nucleotide and/or amino acid sequence data to public or proprietary sequence 25 databases. For example, computerized comparison methods are used to identify sequence motifs or predicted protein conformation domains that occur in other proteins of known structure and/or function. Methods to identify protein sequences that fold into a known three-dimensional structure are known. (Bowie et al., Science 253:164 (1991)). [0018] Preferred amino acid substitutions are those which: (1) reduce susceptibility to 30 proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for forming protein complexes, and (4) confer or modify other physicochemical or functional properties of such analogs. Analogs can include various muteins of a sequence other than the naturally occurring peptide sequence. For example, single or multiple amino acid substitutions (preferably conservative amino acid substitutions) may be made in the WO 2004/099251 PCT/US2004/014276 6 naturally occurring sequence (preferably in the portion of the polypeptide outside the domain(s) forming intermolecular contacts). A conservative amino acid substitution should not substantially change the structural characteristics of the parent sequence (e.g., a replacement amino acid should not tend to break a helix that occurs in the parent 5 sequence, or disrupt other types of secondary structure that characterizes the parent sequence). Examples of art-recognized polypeptide secondary and tertiary structures are described in Proteins, Structures and Molecular Principles (Creighton, Ed., W. H. Freeman and Company, New York (1984)); Introduction to Protein Structure (C. Branden and J. Tooze, eds., Garland Publishing, New York, N.Y. (1991)); and Thornton et al., 10 Nature 354:105 (1991), which are each incorporated herein by reference. [00191 As used herein, the twenty conventional amino acids and their abbreviations follow conventional usage. See Immunology - A Synthesis (2nd Edition, E.S. Golub and D.R. Gren, Eds., Sinauer Associates, Sunderland, Mass. (1991)), which is incorporated herein by reference. Stereoisomers (e.g., D-amino acids) of the twenty conventional 15 amino acids, unnatural amino acids such as a-, a-disubstituted amino acids, N-alkyl amino acids, lactic acid, and other unconventional amino acids may also be suitable components for polypeptides of the present invention. Examples of unconventional amino acids include: 4-hydroxyproline, -- carboxyglutamate, c-N,N,N-trimethyllysine, E-N acetyllysine, 0-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5 20 hydroxylysine, s-N-methylarginine, and other similar amino acids and imino acids (e.g., 4 hydroxyproline). In the polypeptide notation used herein, the lefthand direction is the amino terminal direction and the right-hand direction is the carboxy-terminal direction, in accordance with standard usage and convention. [00201 "Human immunoglobulin molecules" refer to immunoglobulin proteins that have 25 a sequence encoded by human immunoglobulin gene sequences. In some embodiments the protein is encoded by the gum-line human gene sequence mother embodiments the protein may comprise mutations from the human germ-line sequence. [00211 "Human monoclonal antibodies" refer to antibodies that are members of a population of human antibodies with identical specificities. The population of human 30 antibodies may be produced in a hybridoma or other immortalized cell line as well as in recombinant cell lines expressing the exogenous human antibody gene sequences. [0022] "Immunocompromised patients" refer to patients whose immune responses to foreign antigens or agents is impaired, e.g., by disease (e.g. AIDS), by invasive surgery, WO 2004/099251 PCT/US2004/014276 7 by drug therapies in connection with treatments for other conditions (e.g. organ transplant patients), or due to genetic defects. [0023] "Toxins" refer to protein or non-protein compounds that can be attached to antibodies for the purpose of killing the cells to which the antibodies have attached. 5 Examples of toxins include, but are not limited to, complement, antibiotics, peptides, polysaccharides, lipids, organic polymers, radiolabels, and inorganic compounds. [0024] "Vectors" refer to nucleic acid molecules that allow nucleic acid sequences of interest to be cloned, propagated, recombined, mutated, or expressed outside of their native cells. Often vectors have sequences that allow for controlling expression of gene 10 sequences under specific conditions or in specific cells. [0025] To express the antibodies, or antibody portions of the invention, DNAs encoding partial or full-length light and heavy chains, obtained as described above, are inserted into expression vectors such that the genes are operatively linked to transcriptional and translational control sequences. Expression vectors include plasmids, viruses, 15 retroviruses, cosmids, YACs, EBV-derived episomes, and the like. The antibody gene is ligated into a vector such that transcriptional and translational control sequences within the vector serve their intended function of regulating the transcription and translation of the antibody gene. The expression vector and expression control sequences are chosen to be compatible with the expression host cell used. The antibody light chain gene and the 20 antibody heavy chain gene can be inserted into separate vectors. In a preferred embodiment, both genes are inserted into the same expression vector. The antibody genes are inserted into the expression vector by standard methods (e.g., ligation of complementary restriction sites on the antibody gene fragment and vector, or blunt end ligation if no restriction sites are present). 25 [0026] A convenient vector is one that encodes a functionally complete human CH or CL immunoglobulin sequence, with appropriate restriction sites engineered so that any VH or VL sequence can easily be inserted and expressed, as described above. In such vectors, splicing usually occurs between the splice donor site in the inserted J region and the splice acceptor site preceding the human C domain, and also at the splice regions that occur 30 within the human CH exons. Polyadenylation and transcription termination occur at native chromosomal sites downstream of the coding regions. The recombinant expression vector also can encode a signal peptide that facilitates secretion of the antibody chain from a host cell. The antibody chain gene may be cloned into the vector such that the signal peptide is linked in-frame to the amino terminus of the immunoglobulin chain. The signal peptide WO 2004/099251 PCT/US2004/014276 8 can be an immunoglobulin signal peptide or a heterologous signal peptide (i.e., a signal peptide from a non-immunoglobulin protein). [00271 In addition to the antibody chain genes, the recombinant expression vectors of the invention carry regulatory sequences that control the expression of the antibody chain 5 genes in a host cell. It will be appreciated by those skilled in the art that the design of the expression vector, including the selection of regulatory sequences may depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. Exemplary regulatory sequences for mammalian host cell expression include viral elements that direct high levels of protein expression in mammalian cells, such as 10 promoters and/or enhancers derived from retroviral LTRs, cytomegalovirus (CMV) (such as the CMV promoter/enhancer), Simian Virus 40 (SV40) (such as the SV40 promoter/enhancer), adenovirus, (e.g., the adenovirus major late promoter (AdMLP)), polyoma and strong mammalian promoters such as native immunoglobulin and actin promoters. For further description of viral regulatory elements, and sequences thereof, 15 see, e.g., U.S. Patent No. 5,168,062 by Stinski, U.S. Patent No. 4,510,245 by Bell et al. and U.S. Patent No. 4,968,615 by Schaffner et al. [00281 In addition to the antibody chain genes and regulatory sequences, the recombinant expression vectors of the invention may carry additional sequences, such as sequences that regulate replication of the vector in host cells (e.g., origins of replication) 20 and selectable marker genes. The selectable marker gene facilitates selection of host cells into which the vector has been introduced (see e.g., U.S. Patent Nos. 4,399,216, 4,634,665 and 5,179,017, all by Axel et al.). For example, typically the selectable marker gene confers resistance to drugs, such as G418, hygromycin or methotrexate, on a host cell into which the vector has been introduced. Exemplary selectable marker genes include the 25 dihydrofolate reductase (DHFR) gene (for use in dhfr- host cells with methotrexate selection/amplification), the neo gene (for G418 selection), and the glutamate synthetase gene. [0029] Nucleic acid molecules encoding anti-GXM antibodies and vectors comprising these nucleic acid molecules can be used for transfection of a suitable mammalian host 30 cell. Transformation can be by any known method for introducing polynucleotides into a host cell. Methods for introduction of heterologous polynucleotides into mammalian cells are well known in the art and include dextran-mediated transfection, calcium phosphate precipitation, polybrene-mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA WO 2004/099251 PCT/US2004/014276 9 into nuclei. In addition, nucleic acid molecules may be introduced into mammalian cells by viral vectors. Methods of transforming cells are well known in the art. See, e.g., U.S. Patent Nos. 4,399,216, 4,912,040, 4,740,461, and 4,959,455 (which patents are hereby incorporated herein by reference). 5 [0030] Mammalian cell lines available as hosts for expression are well known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC). These include, inter alia, Chinese hamster ovary (CHO) cells, NSO, SP2 cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), A549 cells, and a number of other 10 cell lines. Cell lines of particular preference are selected through determining which cell lines have high expression levels. Other cell lines that may be used are insect cell lines, such as Sf9 cells. When recombinant expression vectors encoding antibody genes are introduced into mammalian host cells, the antibodies are produced by culturing the host cells for a period of time sufficient to allow for expression of the antibody in the host cells 15 or, more preferably, secretion of the antibody into the culture medium in which the host cells are grown. Antibodies can be recovered from the culture medium using standard protein purification methods. [00311 Further, expression of antibodies of the invention (or other moieties therefrom) from production cell lines can be enhanced using a number of known techniques. For 20 example, the glutamine synthetase gene expression system (the GS system) is a common approach for enhancing expression under certain conditions. The GS system is discussed in whole or part in connection with European Patent Nos. 0 216 846, 0 256 055, and 0 323 997 and European Patent Application No. 89303964.4. [0032] "Operably linked" sequences include both expression control sequences that are 25 contiguous with the gene of interest and expression control sequences that act in trans or at a distance to control the gene of interest. The term "expression control sequence" as used herein refers to sequences that allow for the inducible or constitutive expression of gene sequences under specific conditions or in specific cells. Examples of cellular processes that expression control sequences regulate include, but are not limited to, gene 30 transcription, protein translation, messenger RNA splicing, immunoglobulin isotype switching, protein glycosylation, protein cleavage, protein secretion, intracellular protein localization and extracellular protein homing. Expression control sequences include appropriate transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences WO 2004/099251 PCT/US2004/014276 10 that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (i.e., Kozak consensus sequence); sequences that enhance protein stability; and when desired, sequences that enhance protein secretion. The nature of such control sequences differs depending upon the host organism. In prokaryotes, such control sequences generally 5 include promoter, ribosomal binding site, and transcription termination sequence. In eukaryotes, generally, such control sequences include promoters and transcription termination sequence. The term "control sequences" is intended to include, at a minimum, all components whose presence is essential for expression and processing, and can also include additional components whose presence is advantageous, for example, leader 10 sequences and fusion partner sequences. [0033] The term "recombinant host cell" (or simply "host cell"), as used herein, is intended to refer to a cell into which a recombinant expression vector has been introduced. It should be understood that such terms are intended to refer not only to the particular subject cell but to the progeny of such a cell. Because certain modifications may occur in 15 succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term "host cell" as used herein. [0034] "XenoMousev" mice refers to mice bearing inactivated endogenous immunoglobulin loci, rendering them incapable of expressing endogenous murine 20 immunoglobulin, but bearing substantial portions of human immunoglobulin loci. Mice of the XenoMouseV line are capable of somatic rearrangement of the human immunoglobulin genes, hypermutation of the human immunoglobulin variable regions, and immunoglobulin isotype switching. Therefore, the mice of the XenoMouse line are capable of mounting effective humoral responses to antigenic challenge utilizing the 25 human immunoglobulin gene sequences. The resulting antibodies are fully human and can be isolated from the animals themselves, from cultured cells extracted from the animals, or from hybridomas created from XenoMouse mouse B lymphocytic lines or progeny thereof. Moreover, the rearranged human gene sequences encoding immunoglobulins raised against specific antigenic challenges can be isolated by recombinant means well 30 known in the art. [0035] Antibody Structure. The basic antibody structural unit comprises a tetramer. Each tetramer is composed of two pairs of polypeptide chains, each pair having one WO 2004/099251 PCT/US2004/014276 11 "light" (about 25 kDa) and one "heavy" chain (about 50-70 kDa). The amino-terminal portion of each chain includes a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The carboxy-terminal portion of each chain defines a constant region primarily responsible for effector function. Human light chains 5 are classified as kappa and lambda light chains. Heavy chains are classified as mu, delta, gamma, alpha, or epsilon, and define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively. Within light and heavy chains, the variable and constant regions are joined by a "J" region of about 12 or more amino acids, with the heavy chain also including a "D" region of about 10 more amino acids. See, generally, Immunology, Ch. 4 10 (Roitt, I., et al., eds., 6th ed., Harcourt Publishers Ltd., London (2001)) (incorporated by reference in its entirety for all purposes). The variable regions of each light/heavy chain pair form the antibody binding site. Thus, an intact IgG antibody has two binding sites. Except in bifunctional or bispecific antibodies, the two binding sites are the same. [00361 The chains all exhibit the same general structure of relatively conserved 15 framework regions (FR) joined by three hyper variable regions, also called CDRs. The CDRs from the two chains of each pair are aligned by the framework regions, enabling binding to a specific epitope. From N-terminal to C-terminal, both light and heavy chains comprise the domains FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. The assignment of amino acids to each domain is in accordance with the definitions of the Kabat Database of 20 Sequences of Proteins of Immunological Interest (Johnson & Wu, Nucl. Acids Res. 29:205-06 (2001); or Chothia & Lesk, J Mol. Biol. 196:901-17 (1987); Chothia et al. Nature 342:878-83 (1989)). [00371 A bispecific or bifunctional antibody is an artificial hybrid antibody having two different heavy/light chain pairs and two different binding sites. Bispecific antibodies can 25 be produced by a variety of methods including fusion of hybridomas or linking of Fab' fragments. See, e.g., Songsivilai & Lachmann, Clin. Exp. Immunol. 79:315-21 (1990); Kostelny et al., J. Immunol. 148:1547-53 (1992). In addition, bispecific antibodies may be formed as "diabodies" (Holliger et al., Proc. Natl. Acad. Sci. US.A. 90:6444-48 (1993)); or "Janusins" (Traunecker et al., EMBO J. 10:3655-59 (1991) and Traunecker et al., Intl. 30 J Cancer Suppl. 7:51-52 (1992)). Production of bispecific antibodies can be a relatively labor intensive process compared with production of conventional antibodies and yields and degree of purity are generally lower for bispecific antibodies. Bispecific antibodies do not exist in the form of fragments having a single binding site (e.g., Fab, Fab', and Fv).

WO 2004/099251 PCT/US2004/014276 12 [0038] Human Antibodiesfrom Non-human Animals. Antibodies with murine or rat variable and/or constant regions are less useful than human antibodies for certain therapeutic uses. The presence of such murine or rat derived proteins can lead to the rapid clearance of the antibodies or can lead to the generation of an immune response against the 5 antibody by a patient. To avoid these problems with murine or rat derived antibodies, one can, e.g., develop humanized antibodies or generate fully human antibodies through the introduction of human antibody function into a rodent so that the rodent would produce fully human antibodies. 10039] The ability to clone and reconstruct megabase-sized human loci in YACs and to 10 introduce them into the mouse germline provides a powerful approach to elucidating the functional components of very large or crudely mapped loci as well as generating useful models of human disease. Furthermore, the utilization of such technology for substitution of mouse loci with their human equivalents could provide unique insights into the expression and regulation of human gene products during development, their 15 communication with other systems, and their involvement in disease induction and progression. [00401 An important practical application of such a strategy is the "humanization" of the mouse humoral immune system. Introduction of human immunoglobulin (Ig) loci into mice in which the endogenous Ig genes have been inactivated offers the opportunity to 20 study the mechanisms underlying programmed expression and assembly of antibodies as well as their role in B-cell development. Furthermore, such a strategy could provide an ideal source for production of fully human monoclonal antibodies (Mabs) - an important milestone towards fulfilling the promise of antibody therapy in human disease. Fully human antibodies are expected to minimize the immunogenic and allergic responses 25 intrinsic to mouse or mouse-derivatized Mabs and thus to increase the efficacy and safety of the administered antibodies. The use of fully human antibodies can therefore be expected to provide a substantial advantage in the treatment of chronic or recurring human diseases, such as inflammation, autoimmunity, cancer and bacterial infections, which potentially require repeated antibody administrations. 30 [0041] One approach toward this goal was to engineer mouse strains deficient in mouse antibody production with large fragments of the human Ig loci in anticipation that such mice would produce a large repertoire of human antibodies in the absence of mouse antibodies. Large human Ig fragments would preserve the large variable gene diversity as well as the proper regulation of antibody production and expression. By exploiting the WO 2004/099251 PCT/US2004/014276 13 mouse machinery for antibody diversification and selection and the lack of immunological tolerance to human proteins, the reproduced human antibody repertoire in these mouse strains should yield high affinity antibodies against any antigen of interest, including human antigens. Using hybridoma technology, antigen-specific human Mabs with the 5 desired specificity could be readily produced and selected. [0042] This general strategy was demonstrated in connection with the generation of the first XenoMouse& animal strains. See Green et al., Nature Genet. 7:13-21 (1994). The XenoMouse® animal strains were engineered with yeast artificial chromosomes (YACs) containing 245 kb- and 190 kb-sized germline configuration fragments of the human 10 heavy chain locus and kappa light chain locus, respectively, which contained core variable and constant region sequences. Id. The human Ig containing YACs were compatible with the mouse system for both rearrangement and expression of antibodies and were capable of substituting for the inactivated mouse Ig genes. This was demonstrated by their ability to induce B-cell development, to produce an adult-like human repertoire of fully human 15 antibodies, and to generate antigen-specific human monoclonal antibodies. These results also suggested that introduction of larger portions of the human Ig loci containing greater numbers of V genes, additional regulatory elements, and human Ig constant regions might recapitulate substantially the full repertoire that is characteristic of the human humoral response to infection and immunization. 20 [0043] The work of Green et al. was recently extended to the introduction of greater than approximately 80% of the human antibody repertoire through introduction of megabase sized, germline configuration YAC fragments of the human heavy chain loci and kappa light chain loci, respectively, to produce new XenoMouseD mice. See Mendez et al., Nature Genet. 15:146-56 (1997) and Green & Jakobovits, J. Exp. Med. 188:483-95 (1998) 25 the disclosures of which are hereby incorporated by reference. [00441 Such an approach is further discussed and delineated in U.S. Patents 5,916,771, 5,939,598, 5,985,615, 5,998,209, 6,075,181, 6,091,001, 6,114,598 and 6,130,364. See also WO 91/10741, published July 25, 1991, WO 94/02602, published February 3, 1994, WO 96/34096 and WO 96/33735, both published October 31, 1996, WO 98/16654, 30 published April 23, 1998, WO 98/24893, published June 11, 1998, WO 98/50433, published November 12, 1998, WO 99/45031, published September 10, 1999, WO 99/53049, published October 21, 1999, WO 00 09560, published February 24, 2000 and WO 2004/099251 PCT/US2004/014276 14 WO 00/037504, published June 29, 2000. The disclosures of each of the above-cited patents, applications, and references are hereby incorporated by reference in their entirety. [0045] Antibodies in accordance with the present invention are preferably prepared through the utilization of a transgenic mouse that has a substantial portion of the human 5 antibody producing genome inserted but that is rendered deficient in the production of endogenous, murine antibodies. Such mice, then, are capable of producing human immunoglobulin molecules and antibodies and are deficient in the production of murine immunoglobulin molecules and antibodies. Technologies utilized for achieving the same are disclosed in the above-mentioned patents, applications, and references. 10 100461 Through use of such technology, fully human monoclonal antibodies to C. neoformans GXM, or the antigen binding portions thereof, were produced. Essentially, we immunized XenoMouse@ lines of mice with C. neoformans GXM, recovered spleen and lymph node cells (such as B-cells) from the mice that express C. neoformans GXM specific antibodies, fused such recovered cells with nonsecreting myeloma cells to prepare 15 immortal hybridoma cell lines, and screened hybridoma cell lines to identify those that produce antibodies specific to C. neoformans GXM. [00471 Antibodies in accordance with the present invention also can be expressed in cell lines other than hybridoma cell lines. Sequences encoding particular antibodies can be used for transformation of a suitable host cell. Transformation can be by any known 20 method for introducing polynucleotides into a host cell, for example, packaging the polynucleotide in a virus (or into a viral vector) and transducing a host cell with the virus (or vector) or by transfection procedures known in the art, as exemplified by United States Patent Nos. 4,399,216, 4,912,040, 4,740,461, and 4,959,455 (which patents are hereby incorporated herein by reference). The transformation procedure used in a given instance 25 depends upon the host to be transformed. For example, methods for introducing heterologous polynucleotides into mammalian cells are well known in the art and include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei. 30 [00481 Mammalian cell lines available as hosts for expression are well known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC), including but not limited to Chinese hamster ovary (CHO) cells, NS/O, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human WO 2004/099251 PCT/US2004/014276 15 hepatocellular carcinoma cells (e.g., Hep G2), and a number of other cell lines. Cell lines of particular preference are selected through determining which cell lines have high expression levels and produce antibodies with the desired C. neoformans GXM binding properties. 5 [0049] Further, expression of antibodies of the invention (or other moieties therefrom) from production cell lines can be enhanced using a number of known techniques. For example, enhanced expression can be realized by the coamplification expression system utilizing dihydrofolate reductase (DHFR) or the glutamine synthetase gene expression system (the GS system). See, e.g., Kaufman and Sharp, J Mol. Biol. 159:601-21 (1982); 10 European Patent Nos. 0 216 846, 0 256 055, and 0 323 997; and European Patent Application No. 89303964.4. [0050] Antibodies of the invention also can be produced through the generation of an animal or plant that is transgenic for the immunoglobulin heavy and light chain sequences of interest and production of the antibody in a recoverable form therefrom. In connection 15 with the transgenic production in animals, e.g., antibodies can be produced in, and recovered from, the milk of goats, cows, or other mammals. See, e.g., U.S. Patent Nos. 5,827,690, 5,756,687, 5,750,172, and 5,741,957. [0051] The invention contemplates an isolated human monoclonal antibody or antigen binding portion thereof that specifically binds to C. neoformans GXM. In some 20 embodiments, the isolated human antibody or antigen-binding portion thereof binds C. neoformans GXM and enhances resistance of a subject to C. neoformans. [00521 The invention contemplates an isolated human antibody or antigen-binding portion thereof that specifically binds to C. neoformans GXM, wherein the antibody or antigen-binding portion thereof prevents or reduces the severity of conditions or disorders 25 caused by C. neoformans infection. [0053] The isolated human antibody or antigen-binding portion thereof that specifically binds to C. neoformans GXM of the invention may be immunoglobulin G (IgG), IgM, IgE, IgA or IgD. In some embodiments, the IgA may be an IgAl or IgA2 subtype and the IgG may be an IgG1, IgG2, IgG3 or IgG4 subtype. 30 [00541 The invention contemplates an isolated human antibody or antigen-binding portion thereof that specifically binds to C. neoformans GXM and is labeled. In a preferred embodiment, the label is a radiolabel, an enzyme label, a fluorescent label, a toxin, a magnetic agent, a second antibody, an affinity label, an epitope tag, an antibiotic, a complement protein or a cytokine.

WO 2004/099251 PCT/US2004/014276 16 [00551 The invention contemplates an isolated human antibody or antigen-binding portion thereof that specifically binds to C. neoformans GXM and comprises a kappa light chain. In some embodiments, the variable (V) region of the kappa light chain comprises an amino acid sequences is encoded by a human VWIII DPK22/A27 gene with up to 5 5 mutations from the germ-line sequence. In some embodiments, the joining (J) region of the kappa light chain comprises an amino acid sequence that is encoded by a human JK 1 gene. Where the amino acid sequence comprises mutations from the germline VK and/or JK sequences, the mutations can be in framework regions, CDR5 or both. 100561 The invention contemplates an isolated human antibody or antigen-binding 10 portion thereof that specifically binds to C. neoformans GXM and comprises a kappa light chain comprising an amino acid sequence shown in Table 3 (SEQ ID NO: 1; SEQ ID NO: 5; SEQ ID NO: 9) or the variable region thereof. The invention also contemplates an isolated human antibody or antigen-binding portion thereof that specifically binds to C. neoformans GXM and comprises a kappa light chain comprising the CDR1 and CDR3 15 amino acid sequences shown for Mabs G14F7E5, G15B4G5 and G19B9G7 in Table 3 (SEQ ID NOs: 2 and 4; SEQ ID NOs: 6 and 8; and SEQ ID NOs: 10 and 12, respectively). In some embodiments, the antibody comprises a kappa light chain comprising the amino acid sequence from the beginning of the CDR1 through the end of the CDR3 of an amino acid sequence shown in Table 3 (SEQ ID NO: 1, SEQ ID NO: 5; SEQ ID NO: 9). In some 20 embodiments the antibody comprises a kappa light chain comprising the amino acid sequences shown in SEQ ID NOS: 2-4, 6-8 or 10-12. The invention further contemplates an anti C. neoformans GXM antibody comprising the FRI, FR2, FR3 and/or FR4 amino acid sequences in any one of SEQ ID NOS: 1, 5 or 9. The invention further contemplates an isolated human antibody or antigen-binding portion thereof that specifically binds to C. 25 neoformans GXM and comprises a kappa light chain comprising an amino acid sequence encoded by a nucleic acid sequence shown in Table 2 (SEQ ID NO: 13; SEQ ID NO: 17; or SEQ ID NO: 21) or the variable region of said amino acid sequence. A signal sequence may or may not be present in any of the antibodies of the invention. The invention also contemplates an isolated human antibody or antigen-binding portion thereof that 30 specifically binds to C. neoformans GXM and comprises a lambda light chain. [00571 The invention contemplates an isolated human antibody or antigen-binding portion thereof that specifically binds to C. neoformans GXM, comprising a heavy chain composed of variable (V), diversity (D), and joining (J) regions of the G14F7E5, G15B4G5 or G19B9G7 antibody. The invention contemplates an isolated human WO 2004/099251 PCT/US2004/014276 17 antibody or antigen-binding portion thereof that specifically binds to C. neoformans GXM and comprises one or more of the CDR1, CDR2 and CDR3 regions from a heavy chain of the G14F7E5, G15B4G5 or G19B9G7 antibody. [00581 More specifically, the invention contemplates an isolated human antibody or 5 antigen binding portion thereof that specifically binds C. neoformans GXM and comprises a heavy chain that comprises an amino acid sequence that is encoded by a human VH 3 family gene or a human VH6 gene. In some embodiments the human gene is a VH3-64 or a VH6-1 gene. In antibodies utilizing a VH 3 family gene the heavy chain amino acid sequence is preferably the germline VH3 sequence although the invention includes human 10 VH3 utilizing antibodies with up to 3 mutations from the germline sequence. In some embodiments, the heavy chain further comprises an amino acid sequence encoded by a human D3-9 or a human D3-10 gene. In some embodiments the heavy chain further comprises an amino acid sequence encoded by a human JH4b or JH5b gene or said sequence with 1 mutation from the germline sequence. In the case of antibodies utilizing a 15 human VH6-1 gene the antibody sequence can have from 0-6 mutations from germline. Where said amino acid sequences comprise mutations from the germline VH1, D and/or JH sequences, the mutations can be in framework regions CDR5 or both. [00591 In a preferred embodiment, the heavy chain variable region comprises the amino acid sequence encoded by a human VH3-65 gene, a human D3-9 gene and a human JH4b 20 gene. In other embodiments, the heavy chain variable region is encoded by a human VH64 gene, a human D3-10 gene and a human JH5b gene. [00601 The invention further provides an anti-C. neoformans antibody that comprises the amino acid sequences of the heavy chain CDR1, CDR2 and CDR3 of SEQ ID NO: 43 (G14F7E5), SEQ ID NO: 47 (G15B4G5) or SEQ ID NO: 51 (G19B9G7), the amino acid 25 sequence from the beginning of the CDRl through the end of the CDR3 of any one of said SEQ ID NO:s, or the amino acid sequence of the variable region any of said SEQ ID NO:s. [0061] The invention further provides an antibody that specifically binds C. neoformans GXM wherein said antibody comprises a heavy chain comprising the amino acid sequence 30 of the FRI, F2, F3 and/or F4 of any one of SEQ ID NOS 43, 47 or 51. [00621 In some embodiments the affinity of anti-GXM antibodies, expressed as the aKa for GXM 24067 is 1 x 10 3 M- or greater. In some embodiments, the aKa is 1.3 x 103 M-, 2 x 103 M- or 2.1 x 103 M-. As used herein, aKa is the inverse of the soluble GXM antigen concentration at 50% maximal binding to solid-phase antigen.

WO 2004/099251 PCT/US2004/014276 18 [0063] In some embodiments the anti-GXM antibodies of the invention bind soluble cell surface bound GXM from serotype A C. neoformans, for example GXM from strain SB4 and H99. 10064] In some embodiments, the anti-GXM antibodies of the invention mediate C3 5 complement deposition. [0065] In some embodiments the anti-GXM antibodies of the invention show protection against C. neoformans infection. [00661 The invention contemplates an isolated human antibody or antigen-binding portion thereof that specifically binds to C. neoformans GXM and comprises an antigen 10 binding domain chosen from the list consisting of an Fab fragment, an F(ab')2 fragment and an Fv fragment. [0067] The invention contemplates an isolated human antibody or antigen-binding portion thereof that specifically binds to C. neoformans GXM and the antibody is a single chain antibody. 15 [0068] The invention contemplates an isolated human antibody or antigen-binding portion thereof that specifically binds to C. neoformans GXM and the antibody is a chimeric antibody. In a preferred embodiment, the chimeric antibody comprises framework regions and CDR regions from different human antibodies. In a more preferred embodiment, the chimeric antibody is bispecific. In a more preferred 20 embodiment, the chimeric antibody is bispecific for C. neoformans GXM and a label selected from the list consisting of a radiolabeled molecule, an enzymatic label, a fluorescent label, a toxin, a magnetic agent, a second antibody, an affinity label, an epitope tag, an antibiotic, a complement protein and a cytokine. [00691 The invention contemplates an isolated human antibody or antigen-binding 25 portion thereof that specifically binds to C. neoformans GXM wherein the antibody or portion thereof is derivatized. In a preferred embodiment, the antibody or portion thereof is derivatized with polyethylene glycol, at least one methyl or ethyl group or at least one carbohydrate moiety. [0070] One may use the nucleic acid molecules of the invention to generate antibody 30 derivatives using techniques and methods known to one of ordinary skill in the art. [0071] In another embodiment, the nucleic acid molecules, vectors and host cells may be used to make mutated anti-GXM antibodies. The antibodies may be mutated in the variable domains of the heavy and/or light chains to alter a binding property of the antibody. For example, a mutation may be made in one or more of the CDR regions to WO 2004/099251 PCT/US2004/014276 19 increase or decrease the Kd of the antibody for GXM, to increase or decrease Kof, or to alter the binding specificity of the antibody. Techniques in site-directed mutagenesis are well-known in the art. See, e.g., Sambrook et al. and Ausubel et al., supra. If it is desired to introduce mutations in the antibodies, preferably the mutations are made at an amino 5 acid residue that is known to be changed compared to germline in a variable region of an anti-GXM antibody. More preferably one or more mutations are made at an amino acid residue that is known to be changed compared to the germline in a variable region of one of the anti-GXM antibodies of the invention. In another embodiment, the nucleic acid molecules are mutated in one or more of the framework regions. A mutation may be made 10 in a framework region or constant domain to increase the half-life of the anti-GXM antibody. A mutation in a framework region or constant domain may also be made to alter the immunogenicity of the antibody, to eliminate deanudation sites or glycosylation sites to provide a site for covalent or non-covalent binding to another molecule, or to alter such properties as complement fixation. Mutations may be made in each of the framework 15 regions, the constant domain and the variable regions in a single mutated antibody. Alternatively, mutations may be made in only one of the framework regions, the variable regions or the constant domain in a single mutated antibody. [0072] In another embodiment, a fusion antibody or immunoadhesin may be made which comprises all or a portion of an anti-GXM antibody linked to another polypeptide. 20 In a preferred embodiment, only the variable regions of the anti-GXM antibody are linked to the polypeptide. In another preferred embodiment, the VH domain of an anti-GXM antibody is linked to a first polypeptide, while the VL domain of an anti-GXM antibody is linked to a second polypeptide that associates with the first polypeptide in a manner in which the VH and VL domains can interact with one another to form an antibody binding 25 site. In another preferred embodiment, the VH domain is separated from the VL domain by a linker such that the VH and VL domains can interact with one another (see also Single Chain Antibodies). The VH-linker-VL antibody is then linked to the polypeptide of interest. The fusion antibody is useful to detecting GXM. In addition, fusion antibodies can be created in which two (or more) single-chain antibodies are linked to one another. 30 This is useful if one wants to create a divalent or polyvalent antibody on a single polypeptide chain, or if one wants to create a bispecific antibody. In one embodiment, the fusion antibody or immunoadhesin is prepared using one or more CDR regions from an anti-GXM antibody.

WO 2004/099251 PCT/US2004/014276 20 [0073] The invention contemplates a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an isolated human antibody or antigen-binding portion thereof that specifically binds to C. neoformans GXM. The invention further contemplates a kit comprising the antibody or antigen-binding portion thereof, a 5 pharmaceutically acceptable carrier therefor, and a container. In some embodiments, the kit further comprises instructions for use. [00741 The invention contemplates a method for treating or preventing or inhibiting C. neoformans infection or lessening the severity of a condition or disorder caused by such infection, comprising the step of administering an antibody of the invention or an antigen 10 binding portion thereof, or a pharmaceutical composition comprising said antibody or portion to a patient in need thereof, such as a patient who is at risk of being infected with, or currently infected with, C. neoformans. [00751 In some embodiments, the patient is an immunocompromised patient. Immunocompromised patients may be patients whose immune responses is impaired by 15 age, disease or drug treatment, including treatment with immunosuppressing agents or anti-neoplastic or other chemotherapeutic agents. In some embodiments the immunocompromised patient suffers from antibody gene repertoire defects, particularly defects or deficits in the human VH 3 family genes. Patients who may benefit from treatment with an anti-GXM Ab of the invention can be of any age, i.e., infants and 20 children up to elderly patients. [00761 In a preferred embodiment, the human antibody is obtained from a non-human animal. In a more preferred embodiment, the antibody is a monoclonal antibody. In another preferred embodiment, the pharmaceutical composition is administered via injection, transmucosal, oral, inhalation, ocular, rectal, long-acting implantation, 25 liposomes, emulsion, cream, topical or sustained-release means. In another preferred embodiment, the antibody is a fusion with a second protein. In a more preferred embodiment the second protein is chosen from the list consisting of a toxic peptide moiety, a complement protein, a radiolabeled protein, a cytokine or an antibiotic protein. In another preferred embodiment, the antibody is labeled with a radiolabel, a toxin, a 30 complement protein, a cytokine or an antibiotic. In another preferred embodiment, the pharmaceutical composition further comprises a toxin, complement protein, radiolabeled protein, cytokine, antibiotic, or any combination thereof. [00771 The invention contemplates an isolated cell that produces a human antibody or antigen-binding portion thereof that specifically binds to C. neoformans GXM. In some WO 2004/099251 PCT/US2004/014276 21 embodiments, the cell is chosen from the list consisting of a bacterial cell, a yeast cell, an insect cell, an amphibian cell and a mammalian cell. In specific embodiments, the mammalian cell is selected from the list consisting of a human cell, a mouse cell, a rat cell, a dog cell, a monkey cell, a goat cell, a pig cell, a bovine cell and a hamster cell. In other 5 specific embodiments, the mammalian cell is selected from the list consisting of a HeLa cell, a NIH 3T3 cell, a CHO cell, a BHK cell, a VERO cell, a CV-1 cell, a NS/0 cell and a COS cell. In other embodiments, the cell line is a hybridoma. [00781 The invention contemplates a method of producing an isolated human antibody or antigen-binding portion thereof that specifically binds to C. neoformans GXM, 10 comprising: a) culturing a non-human cell capable of producing the antibody under conditions in which the antibody is produced; b) isolating the antibody from the cell culture. [0079] In some embodiments, the method of producing an isolated human antibody or antigen-binding portion thereof that specifically binds to C. neoformans GXM utilizes an 15 immortalized cell line. In some embodiments, the immortalized cell line is a hybridoma. [0080] The invention contemplates the production of additional human antibody or antigen-binding portions thereof that specifically bind to C. neoformans GXM, comprising: a) immunizing a non-human animal comprising a human immunoglobulin locus with a C. neoformans antigenic composition; b) allowing the non-human animal to 20 mount a humoral response to the antigenic composition; and c) isolating the human antibody from the non-human animal. [0081] The invention contemplates a nucleic acid molecule isolated from a non-human animal that comprises a nucleotide sequence that encodes a human antibody heavy chain or the portion thereof that specifically binds to C. neoformans GXM. In some 25 embodiments, the nucleic acid molecule is isolated from a hybridoma that produces the human antibody. [00821 The invention contemplates an isolated nucleic acid molecule, or a fragment thereof, comprising a nucleotide sequence encoding a human antibody heavy chain or antigen-binding portion thereof comprising a nucleotide sequence encoding the heavy 30 chain of G14F7E5, G15B4G5 or G19B9G7 Mab, wherein the human antibody specifically binds to C. neoformans GXM. In a preferred embodiment, the isolated nucleic acid molecule comprises the sequence encoding between one to three of the CDR regions of the human antibody. The invention further contemplates an isolated nucleic acid molecule, or a fragment thereof, comprising a nucleic acid sequence encoding a human WO 2004/099251 PCT/US2004/014276 22 antibody heavy chain or antigen-binding portion thereof comprising a CDR3 amino acid sequence of the G14F7E5, G15B4G5 or G19B9G7 Mab, wherein the human antibody specifically binds to C. neoformans GXM. [0083] The invention contemplates an isolated nucleic acid molecule comprising a 5 nucleotide sequence that encodes a heavy chain and/or a light chain of an anti-C. neoformans antibody or an antigen-binding portion thereof. [0084] In some embodiments, the nucleic acid comprises nucleotide sequences encoding one or more heavy chain or light chain CDR amino acid sequences selected from SEQ ID NOS: 44, 45, 46, 48, 49, 50, 52, 53 or 54. In some embodiments the nucleic acid 10 comprises nucleotide sequences encoding the CDR1, CDR2 and CDR3 amino acid sequence found in any one of SEQ ID NOS: 43, 47 or 51. [0085] In still other embodiments, the nucleic acid comprises a nucleotide sequence encoding the amino acid sequence of any one of SEQ ID NOS: 43, 47 or 51, or of the variable region portion of said sequence. 15 [0086] In some embodiments the nucleic acid comprises a nucleotide sequence encoding the amino acid sequence of the FRI, FR2, FR3 and/or FR4 regions of any one of the SEQ ID NOS: 43, 47 or 51. [0087] In some embodiments, the nucleic acid molecule comprise a nucleotide sequence selected from the group consisting of: SEQ ID NO: 31, SEQ ID NO: 35 and SEQ ID NO: 20 39, or the nucleotide sequence of the variable region, one or more CDRs and/or one or FRs thereof. [0088] The invention contemplates a vector comprising a nucleic acid molecule, or fragment thereof, encoding a human antibody heavy chain or antigen-binding portion thereof, wherein the antibody specifically binds to C. neoformans. In a preferred 25 embodiment, the vector further comprises expression control sequences operably linked to the nucleic acid. [0089] The invention contemplates an isolated nucleic acid molecule, or a fragment thereof, encoding a human antibody light chain or antigen-binding portion thereof comprising a nucleotide sequence as indicated in Table 2 (SEQ ID: 13, SEQ ID: 17, or 30 SEQ ID:21), or the nucleotide sequence of the variable region or one or more FR regions thereof, wherein the antibody specifically binds to C. neoformans GXM. In a preferred embodiment, the isolated nucleic acid molecule comprises the sequence encoding between one to three of the CDR regions of the human antibody. The invention further contemplates an isolated nucleic acid molecule, or a fragment thereof, comprising a WO 2004/099251 PCT/US2004/014276 23 nucleic acid sequence encoding a human antibody light chain or antigen-binding portion thereof comprising the CDR1 and CDR3 amino acid sequence as indicated in Table 3 (SEQ Ms: 2 and 4; SEQ ID NOs: 6 and 8; or SEQ ID NOs: 10 and 12), wherein the human antibody specifically binds to C. neoformans GXM. The invention contemplates 5 an isolated nucleic acid molecule, or a fragment thereof, comprising a nucleic acid sequence encoding a human antibody light chain or antigen-binding portion thereof comprising CDR1 and CDR3 amino acid sequences as indicated in Table 2 for Mabs G14F7E5, G15B4G5 or G19B9G7 (SEQ ID NOs: 14 and 16; SEQ ID NOs: 18 and 20; or SEQ ID NOs: 22 and 24, respectively), wherein the human antibody specifically binds to 10 C. neoformans GXM. [00901 The invention contemplates a vector comprising a nucleic acid molecule, or fragment thereof, encoding a human antibody light chain or antigen-binding portion thereof that specifically binds to C. neoformans. In a preferred embodiment, the vector further comprises an expression control sequence operably linked to the nucleic acid. 15 [0091] The invention contemplates an isolated host cell comprising: a) a nucleic acid molecule that was isolated from a non-human animal and encodes a light chain or the antigen-binding portion thereof of a human antibody that specifically binds to C. neoformans GXM; or b) a vector comprising the nucleic acid molecule. [0092] The invention contemplates an isolated host cell comprising: a) a nucleic acid 20 molecule that was isolated from a non-human animal and encodes a heavy chain or the antigen-binding portion thereof of a human antibody that specifically binds to C. neoformans GXM; or b) a vector comprising the nucleic acid molecule. [00931 The invention contemplates an isolated host cell comprising: a) a nucleic acid molecule that was isolated from a non-human animal and encodes a heavy chain or the 25 antigen-binding portion thereof and an isolated nucleic acid molecule that encodes a light chain or the antigen-binding portion thereof of a human antibody that specifically binds to C. neoformans GXM; or b) a vector or vectors comprising the nucleic acid molecules. [0094] The invention contemplates a method of recombinantly producing the heavy chain or the antigen-binding portion thereof, the light chain or the antigen-binding portion 30 thereof, or both the light chain and heavy chain or antigen-binding portions thereof, of a human antibody that was identified from a non-human animal and specifically binds to C. neoformans GXM, comprising the step of cultivating the host cells described above under conditions in which the nucleic acid molecules are expressed.

WO 2004/099251 PCT/US2004/014276 24 [00951 The invention contemplates an isolated human antibody heavy chain or antigen binding portion thereof, wherein the antibody specifically binds to C. neoformans GXM, encoded by any of the nucleic acid molecules encoding the heavy chain described above, or isolated from any of the host cells described above. 5 [00961 The invention contemplates an isolated human antibody light chain or antigen binding portion thereof, wherein the antibody specifically binds to C. neoformans GXM, encoded by any of the nucleic acid molecules encoding the heavy chain described above, or isolated from any of the host cells described above. [00971 The invention contemplates a non-human transgenic animal comprising any of 10 the nucleic acid molecules described above. In a preferred embodiment, the non-human transgenic animal expresses the nucleic acid molecule or molecules. In a more preferred embodiment, the non-human transgenic animal comprises an isolated nucleic acid molecule that encodes a heavy chain or the antigen-binding portion thereof and an isolated nucleic acid molecule that encodes a light chain or the antigen-binding portion thereof of a 15 human antibody that specifically binds to C. neoformans GXM, and the non-human animal expresses both nucleic acid molecules. In a more preferred embodiment, the non human animal is selected from the list consisting of a mouse, a rat, a hamster, a cow, a sheep, a primate, a horse and a pig. In a more preferred embodiment, a human antibody resulting from expression of the isolated nucleic acid molecules or portions thereof is 20 expressed on the surface of cells derived from the animal's B lymphocytic cells or progeny thereof. In another preferred embodiment, the human antibody resulting from expression of the isolated nucleic acid molecules or a portion thereof is secreted into the lymph, blood, milk, saliva, or ascites of the animal. 100981 The invention contemplates a fusion protein comprising an isolated human 25 antibody or antigen-binding portion thereof that specifically binds to C. neoformans GXM and a second polypeptide sequence. In various embodiments, the second polypeptide sequence is chosen from the list consisting of an epitope tag, an affinity tag, a toxic polypeptide, an antibiotic, an enzyme, a second antibody sequence, a complement protein, and a cytokine. 30 [00991 The invention contemplates an isolated human antibody or antigen-binding portion thereof that specifically binds to C. neoformans GXM, wherein the heavy chain isotype of the antibody is mu, gamma, delta, epsilon or alpha.

WO 2004/099251 PCT/US2004/014276 25 [0100] The invention contemplates an isolated human antibody or antigen-binding portion thereof that specifically binds to C. neoformans GXM, wherein the antibody or antigen-binding portion thereof is produced by a process comprising the steps of: a) immunizing a non-human animal comprising a human immunoglobulin 5 locus with an antigen selected from the group consisting of an C. neoformans GXM preparation, a virulent C. neoformans cell preparation, an attenuated C. neoformans cell preparation, and a killed C. neoformans cell preparation; b) allowing the non-human animal to mount an immune response to the antigen; and c) isolating the antibody from the non-human animal. 10 [0101] The invention contemplates an isolated human antibody or antigen-binding portion thereof isolated from an animal or cell that was free of contaminating human biomaterials such as viruses, enzymes, hormones, cytokines, receptors, receptor ligands, immunoglobulins, complement, nuclear proteins, and cytoplasmic signaling proteins. In particular, the human antibodies of the invention are free of Epstein-Barr virus or 15 retroviruses. [01021 Pharmaceutical compositions may be manufactured by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes. [01031 Pharmaceutical compositions for use in accordance with the present invention 20 thus may be formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. [0104] For injection, the agents of the invention may be formulated in aqueous solutions, 25 preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art. For ocular administration, suspensions in an appropriate saline solution are used as is well known in the art. 30 [01051 For oral administration, the compounds can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. Pharmaceutical preparations for oral use can be obtained as a WO 2004/099251 PCT/US2004/014276 26 solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients include fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice 5 starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. [01061 Dragee cores are provided with suitable coatings. For this purpose, concentrated 10 sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses. 15 [01071 Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds 20 may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration. [01081 For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner. 25 [01091 For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be 30 determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin, for use in an inhaler or insufflator, may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch. [01101 The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be WO 2004/099251 PCT/US2004/014276 27 presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. 5 [01111 Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions 10 may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. [0112] Alternatively, the active ingredient may be in powder form for constitution with a 15 suitable vehicle, such as sterile pyrogen-free water, before use. [01131 The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides. [0114] In addition to the formulations described previously, the compounds may also be 20 formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble 25 salt. [0115] A pharmaceutical carrier for the hydrophobic compounds of the invention is a cosolvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. The cosolvent system may be the VPD co-solvent system. VPD is a solution of 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant 30 polysorbate 80, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol. The VPD co-solvent system (VPD:5W) consists of VPD diluted 1:1 with a 5% dextrose in water solution. This co-solvent system dissolves hydrophobic compounds well, and itself produces low toxicity upon systemic administration. Naturally, the proportions of a co-solvent system may be varied considerably without destroying its WO 2004/099251 PCT/US2004/014276 28 solubility and toxicity characteristics. Furthermore, the identity of the co-solvent components may be varied: for example, other low-toxicity nonpolar surfactants may be used instead of polysorbate 80; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g., polyvinyl 5 pyrrolidone; and other sugars or polysaccharides may be substituted for dextrose. 10116] Alternatively, other delivery systems for hydrophobic pharmaceutical compounds may be employed. Liposomes and emulsions are well known examples of delivery vehicles or carriers for hydrophobic drugs. Certain organic solvents such as dimethylsulfoxide also may be employed, although usually with a greater toxicity. 10 [01171 Additionally, the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. 15 101181 Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed. [01191 The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, 20 gelatin, and polymers such as polyethylene glycols. [0120] The isolated human antibody or an antigen-binding portion thereof that specifically binds to C. neoformans GXM of the invention may be provided as salts with pharmaceutically compatible counterions. Pharmaceutically compatible salts may be formed with many acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, 25 tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents that are the corresponding free base forms. [0121] The kits of the present invention comprise instructions for utilizing the compositions of the present invention for inhibition, prevention or treatment of C. neoformans infections or conditions or disorders caused by such infection. The printed 30 instructions on the kit enable one of skill in the art to utilize the kit for practicing the methods of the present invention. [0122] The following examples are provided by way of illustration only. They are not intended to limit the scope of the invention disclosed herein.

WO 2004/099251 PCT/US2004/014276 29 [0123] Example 1 - Generation of Monoclonal Antibodies to Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan (GXM) 5 [0124] We vaccinated IgG2-kappa human immunoglobulin transgenic mice (XenoMouse mice; Mendez et al., Nat. Genet. 15, pp. 146-56 (1997)) with glucuronoxylomannan of C. neoformans serotype D (Strain 24067, ATCC) conjugated to diphteria toxoid (GXM-DT). Vaccinations were performed subcutaneously at the base of the tail. A 100 ld injection of 10 pg of GXM-DT with 50 pl Alhydrogel and 10 plI CpG 10 was administered to each mouse three times: on days 0, 14 and 28. Splenocytes were isolated from the mice on day 42 and hybridomas were produced by fusion of splenocytes with mouse myeloma cell line NSO according to techniques well known in the art (Pirofski et al., Infect. Immun. 63: 3005-14, 1995; Chang et. al. Infect Immun. 70:4977-86, 2002). Hybridoma cells were cloned in soft agar and propagated using enriched 15 hybridoma medium. [0125] Over 500 hybridoma cell lines were screened for secretion of antibodies that reacted with GXM 24067. Supernatants from cells showing growth were incubated with polystyrene ELISA plates (Coming m Glass Works, Coming, NY) coated with 10 pAg/ml GXM 24067 at 37*C for 1 hour; the plates were washed and incubated at 37'C for 1 hour 20 with alkaline-phosphatase (AP) conjugated goat anti-human reagents to IgG, IgM, kappa light chains and a goat anti-mouse reagent specific for lambda light chains (FisherBiotech", Fisher Scientific , Pittsburgh, PA). The plates were washed and binding was detected with p-nitrophenyl phosphate substrate (Sigma, St. Louis, MO). Optical densities were measured at 405 nm with an MRX Microplate Reader (Dynatech 25 Laboratories, Chantilly, VA). The negative control was an 1gM myeloma antibody (Calbiochem®, San Francisco, CA). GXM-binding hybridomas were tested for binding to various antigens including the GXM-mimotope (P13) as described (Zhang et al., Infect. Immun. 65 1158-64, 1997 and Fleuridor, et al., J. Infect. Dis. 180: 1526-35 (1999), staphylococcal protein A (SPA; Sigma), DT and BSA, using standard techniques as 30 described in (Russell et al., Infect. Immun. 68: 1820-26, 2000, Pirofski et al., Infect. Immun. 63: 3005-14, 1995 and Chang et al., Infect. Immun. 68:1820-26, 2002).

WO 2004/099251 PCT/US2004/014276 30 Example 2 - Characterization of MAbs to cryptococcal GXM [0126] After repeated screening to test for specificity, three hybridomas cell lines were 5 found to have the highest reactivity with GXM and to be reactive with GXM only. The three human MAbs produced by those hybridomas, G14F7E5, G15B4G5 and G19B9G7, were studied further. All three antibodies are IgM and react with GXM 24067 and did not exhibit significant (above background) binding to DT, BSA or the GXM mimotope P13 by direct ELISA. All three MAbs bound to the GXM on C. neoformans cells from strain 10 24067 based on immunofluorescent staining. [0127] The three hybridomas were deposited on May 1, 2003 with the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, VA 20110-2209, U.S.A. under the provisions of the Budapest Treaty for the International Recognition of the Deposit of Microorganism for the Purposes of Patent Procedure. The following ATCC 15 accession numbers were assigned: G14F7E5 PTA-5170 G15B4G5 PTA-5171 G19B9G7 PTA-5172 20 101281 The specificity of the MAbs for C. neoformans serotype A also was determined. Serotype A is the most common cause of cryptococcosis in North America; whereas serotype D is the second most common serotype in North America and is a common cause of disease in Europe. The serotype specificity studies were performed using purified GXM and whole cell ELISAs as follows. 25 101291 Purified GXM ELISA: Serial dilutions of each of the MAbs (beginning at1O pg/ml) were incubated with ELISA plates coated with 10 pg/ml GXM from C. neoformans strain 24067, serotype A strains SB4 and H99 (provided by Dr. Arturo Casadevall, Albert Einstein College of Medicine) or P13-dextran in PBS; plates were washed and incubated with a goat anti-human IgM-AP (Fisher) for 1 hr, washed and developed as above. MAbs 30 G14F7E5 and G19B9G7 reacted with both serotype A strains, whereas G15B4G5 should no appreciable binding to either serotype A strain indicating that the MAbs have different strain specificity. The results of this experiment are shown in Table 1.

WO 2004/099251 PCT/US2004/014276 31 Table 1: Strain Specificity of Reactivity of Mabs G14F7E5, G15B4G5 and G19B9G7 with soluble GXM. C. neoformans strain G14F7E5 G15B4G5 G19B9G7 24067 (serotype D) +++ +++ ++ SB4 (serotype A) ++. +++ H99 (serotype A) +++ [01301 Whole Cell ELISA: C. neoformans strains 24067, SB4 and H99 were grown in Saboraud dextrose broth (Becton Dickinson, Sparks MD) for 2 days, after which the cells 5 were washed in PBS, counted and heat-killed at 68'C for 2 h. Cell death was verified by incubating heat-killed cells in Saboraud dextrose broth overnight at 3 1C. The cells were diluted in PBS, plated into ELISA plates at a concentration of 1x10 7 cfu/ml (50 pl/well) and the plates were incubated overnight at 4'C. As controls a myeloma IgM (Calbiochem) and an anti-PPS8 monoclonal IgM, D1I were used. Unbound cells were removed and 10 bound cells were fixed to the plates by incubation with 150 1d/ well of methanol for 30 min. Plates were washed and blocked with 1% BSA/PBS for I h at 37'C. After washing, MAbs or a control myeloma IgM (Calbiochem, San Diego, CA) were added to the plates at an initial concentration of 10 ptg/ml, diluted 1:3 and they were incubated for 1 h at 37'C. After washing, the plates were incubated with a 1:1000 dilution (in 0.1% BSA/PBS) of 15 goat anti-human IgM AP-conjugated for 1 h at 37 0 C. Plates were developed as above and read at a wavelength of 405 nm. [0131] All three of the MAbs bound to both serotype A strains although mAb G15B4G5 bound to a lesser degree than the other two mAbs. 20 [0132] Example 3 - Antigen Specificity [0133] The GXM specificity of the MAbs was confirmed with an inhibition ELISA. As controls, a human myeloma IgM (see above) and D 11, which is an IgM specific for serotype 8 of Streptococcus pneumoniae (Zhong et al., Infect. Immun. 67:4119-27, 1999) 25 were used. ELISA plates, coated with 10 pg/ml of the GXMs (24067 SB4 or H99) or 10 ig/ml of P13-DEX (a dextran conjugate of a previously reported polypeptide GXM mimetope; Fleuridor et al., J. Immunol. 166: 1087-96 (2001); Maitta et al., Infection Immun. 72: 196-208 (2004)) for 3 hours at room temperature, washed and blocked with 1% BSA/PBS overnight at 4'C. Plates were incubated with serial dilutions of the soluble WO 2004/099251 PCT/US2004/014276 32 GXMs mixed (beginning with 100 pg/ml) with the MAbs 10 or 1 tg/ml; the plates were washed, incubated with goat-anti-human IgM-AP (Fisher) for 1 hr at 37*C and developed and read as above. [0134] As shown in Fig. 1, soluble GXM from strain SB4 did not inhibit binding of any 5 of the mAbs to GXM from strain 24067 (panel A). [0135] Example 4 - Sequence Analysis of MAbs to C. neoformans GXM 24067 [0136] We obtained the nucleotide sequences for the light chain variable regions (VL) Of 10 the MAbs by sequencing PCR-amplified VL cDNA from the hybridomas. We generated VL cDNA by reverse transcription of RNA using the VL specific primers: VK sense, 5'- GAA(CT)ATC(T)GAGCTCACC(GT)CAGTCTCCA-3'(SEQ ID NO: 25; (CT) indicates that position 3 has an equal frequency of being A, C or T; the (T) indicates that position 6 has an equal frequency of being C or T; (GT) indicates that position 15 has an 15 equal frequency of being C, G or T); VK anti-sense, 5'-CCTGTTGAAGCTCTTTGTGAC-3' (SEQ ID NO: 26). PCR products were sequenced from two independent experiments and were found to be identical. The nucleotide sequences comprising the variable regions and CDRs of G14F7E5, G15B4G5 and G19B9G7 are indicated below in Table 2. The amino acid sequences comprising the 20 variable regions and CDRs of G14F7E5, G15B4G5 and G19B9G7 are shown below in Table 3. We compared the variable-region sequences to the database of human immunoglobulin sequences using DNA PLOT (V Base Index; MRC Center for Protein Engineering, Cambridge, United Kingdom; Mukherjee et al., J. Exp. Med. 177:1105-16 (1993)). 25 WO 2004/099251 PCT/US2004/014276 33 Table 2: Nucleic Acid Sequences of Light Chains of Mabs G14F7E5, G15B4G5 and G19B9G7. Identity of Nucleic Acid Sequence SEQ ID NO: Sequence G14F7E5 5'- GGCACCCTGT CTTTGTCTCC AGGGGAAAGA 13 variable GCCACCCTCT CCTGCAGGGC CAGTCAGAGT region GTTATCAGCA GCTACTTAGC CTGGTACCAG CAGAAACCTG GCCAGGCTCC CAGGCTCCTC ATCTATGGTG CATCCAGCAG GGCCACTGGC ATCCCAGACA GGTTCAGTGG CAGTGGGTCT GGGACAGACT TCACTCTCAC CATCAGCAGA CTGGAGCCTG AAGATTTTGC AGTGTATTAC TGTCAGCAGT ATGGTAACTC ACGGACGTTC GGCCAAGGGA CCAAGGTGGA AATCAAACGA ACTGTGGCTG CACCATCTGT CTTCATCTTC CCGCCATCTG ATGAGCAGTT GAAATCTGGA ACTGCCTCTG TTGTGTGCCT GCTGAATAAC TTCTATCCCA GAGAGGCCAA AGTACAGTGG AAGGTGGATA ACGCCCTCCA ATCGGGTAAC TCCCAGGAGA GTGTCACAGA GCAGGACAGC AAGGACAGCA CCTACAGCCT CAGCAGCACC CTGACGCTGA GCAAAGCAGA CTACGAAGAA ACACAAAGTT CTACGCCTGC GAAGGTNANN NATCAG -3' G14F7E5 5'- AGGGCCAGTC AGAGTGTTAT CAGCAGCTAC 14 CDRI TTAGCC -3' G14F7E5 5'- GGTGCATCCA GCAGGGCCAC T -3' 15 CDR2 G14F7E5 5'- CAGCAGTATG GTAACTCACG GACG -3' 16 CDR3 G15B4G5 5'- CAGTCTCCAG GCACCCTGTC TTTGTCTCCA 17 variable GGGGAAAGAG CCACCCTCTC CTGCAGGGCC region AGTCAGAGTG TTAGCAGCAG CTACTTAGCC TGGTACCAGC AGAAACCTGG CCAGGCTCCC AGGCTCCTCA TCTATGGTGC ATCCAGCAGG GCCACTGGCA TCCCAGACAG GTTCAGTGGC AGTGGGTCTG GGACAGACTT CACTCTCACC ATCAGCAGAC TGGAGCCTGA AGATTTTGCA GTGTATTACT GTCAGCAGTA TGGTAGCTCA CGGACGTTCG GCCAAGGGAC CAAGGTGGAA ATCAAACGAA CTGTGGCTGC ACCATCTGTC TTCATCTTCC CGCCATCTGA TGAGCAGTTG AAATCTGGAA CTGCCTCTGT TGTGTGCCTG CTGAATAACT TCTATCCCAG AGAGGCCAAA GTACAGTGGA AGGTGGATAA CGCCCTCCAA TCGGGTAACT CCCAGGAGAG TGTCACAGAG CAGGACAGCA AGGACAGCAC CTACAGCCCT CAGCAGCACC CTGACGCTGA AGCAAAAGCA WO 2004/099251 PCT/US2004/014276 34 Identity of Nucleic Acid Sequence SEQ ID NO: Sequence GACTACGAAG AAACACAAAG GTTCTACGCC TGCGAANGGT CAANACCAT -3' G15B4G5 5'- AGGGCCAGTC AGAGTGTTAG CAGCAGCTAC 18 CDR1 TTAGCC-3' G15B4G5 5'- GGTGCATCCA GCAGGGCCAC T -3' 19 CDR2 G15B4G5 5'- CAGCAGTATG GTAGCTCACG GACG -3' 20 CDR3 G19B9G7 5'- TCTTTGTCTC CAGGGGAAAG AGCCACCCTC 21 variable TCCTGCAGGA CCAGTCAGAG TATTACCAAC region AGCTACTTAG CCTGGTACCA GCAGAAACCT GGCCAGGCTC CCAGGCTCCT CATCTATGGT GCATCCAGCA GGGCCACTGG CATCCCAGAC AGGTTCAGTG GCAGTGGGTC TGGGACAGAC TTCACTCTCA CCATCAGCAG ACTGGAGCCT GAAGATTTTG CAGTGTATTA CTGTCAGCAG TATGGTAACT CACGGACGTT CGGCCAAGGG ACCAAGGTGG AAATCAAACG AACTGTGGCT GCACCATCTG TCTTCATCTT CCCGCCATCT GATGAGCAGT TGAAATCTGG AACTGCCTCT GTTGTGTGCC TGCTGAATAA CTTCTATCCC AGAGAGGCCA AAGTACAGTG GAAGGTGGAT AACGCCCTCC AATCGGGTAA CTCCCAGGAG AGTGTCACAG AGCAGGACAG CAAGGACAGC ACCTACAGCC TCAGCAGCAC CCTGACGCTG AGCAAAGCAG ACTACGAAGA AACACAAAGT TCTACGCCTG CGAAAGGTNN AANANNGATC AAGGG -3' G19B9G7 5'- AGGACCAGTC AGAGTATTAC CAACAGCTAC 22 CDR1 TTAGCC -3' G19B9G7 5'- GGTGCATCCA GCAGGGCCAC T -3' 23 CDR2 G19B9G7 5'- CAGCAGTATG GTAACTCACG GACG -3' 24 CDR3 WO 2004/099251 PCT/US2004/014276 35 Table 3: Amino Acid Sequences of Light Chains of Mabs G14F7E5, G15B4G5 and G19B9G7. Identity of Amino Acid Sequence SEQ ID NO: Sequence G14F7E5 GTLSLSPGER ATLSCRASQS VISSYLAWYQ 1 variable QKPGQAPRLL IYGASSRATG IPDRFSGSGS region GTDFTLTISR LEPEDFAVYY COOYGNSRTF GQGTKVEIKR TVAAPSVFIF PPSDEQLKSG TASVVCLLNN FYPREAKVQW KVDNALQSGN SQESVTEQDS KDSTYSLSST LTLSKADYEE TQSSTPAKVX XQ G14F7E5 RASQSVISSY LA 2 CDR1 G14F7E5 GASSRAT 3 CDR2 G14F7E5 QQYGNSRT 4 CDR3 G15B4G5 QSPGTLSLSP GERATLSCRA SQSVSSSYLA 5 variable WYQQKPGQAP RLLIYGASSR ATGIPDRFSG region SGSGTDFTLT ISRLEPEDFA VYYCOOYGSS RTFGQGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSP QQHPDAEAKA DYEETQRFYA CEXSXP G15B4G5 RASQSVSSSY LA 6 CDR1 G15B4G5 GASSRAT 7 CDR2 G15B4G5 QQYGSSRT 8 CDR3 G19B9G7 SLSPGERATL SCRTSOSITN SYLAWYQQKP 9 variable GQAPRLLIYG ASSRATGIPD RFSGSGSGTD region FTLTISRLEP EDFAVYYCQQ YGNSRTFGQG TKVEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEETQS STPAKGXXXI K G19B9G7 RTSQSITNSY LA 10 CDRI G19B9G7 GASSRAT 11 CDR2 I G19B9G7 QQYGNSRT 12 CDR3 [01371 The VL chain variable region gene transcripts of all three MAbs, utilize a human 5 VKA27 (DPK22) gene and a human JKI light-chain gene element. Sequence comparisons WO 2004/099251 PCT/US2004/014276 36 show that G15B4G5 has a germline A27 sequence. In contrast, both G14F7E5 and G1 9B9G7 have the same nucleotide substitution in the CDR3 region, G to A (position 257 in SEQ ID NO: 13 and position 248 in SEQ ID NO: 21). G15B4G5, lacks this substitution. This substitution results in an amino acid change from Serine (S) to 5 Asparagine (N) (position 86 in SEQ ID NO: I and position 83 in SEQ ID NO: 9), Sequence comparisons show that G14F7E5 has a single nucleotide substitution in CDR1 from G to T (position 65 in SEQ ID NO: 13). This substitution results in an amino acid change from Serine (S) to Isoleucine (I) (position 22 in SEQ ID NO: 1). G19B9G7 has four substitutions in the CDRl: from G to A at positions 40, 52 and 59 in SEQ ID NO: 13, 10 and from G to C at position 56 in SEQ ID NO: 13. These substitutions result in amino acid changes as follows: from Alanine (A) to Threonine (T) at position 14 in SEQ ID NO: 9; from Valine (V) to Isoleucine (I) at position 18 in SEQ ID NO: 9; from Serine (S) to Threonine (T) at position 19 in SEQ ID NO: 9; and from Serine (S) to Asparagine (N) at position 20 in SEQ ID NO: 9. 15 [0138] We determined the VH gene sequences from PCR-amplified VH gene cDNA from the hybridomas producing Mabs G14F7E5, G15B4G5 and G19B9G7 as follows. We generated VH cDNA by reverse transcription of RNA using VH constant region primers. We then amplified the VH region from the cDNA by PCR using a mixture of VH specific primers which collectively cover all of the VH genes in the XenomouseR mice used: 20 VH 3 -0 7 sense, 5'-CACCATGGARTTGGGGCTGAGCTGG-3' (SEQ ID NO: 29); VH3-09 sense, 5'-CACCATGGAGTTKGGACTGAGCTGG-3' (SEQ ID NO: 55); VH3-11 sense, 5'-CACCATGGAGTTTGGGCTKAGCTGG-3' (SEQ ID NO: 56); VH3-21 sense, 5'-CACCATGGAACTGGGGCTCCGCTGG-3' (SEQ ID NO: 57); VH3- 4 8 sense, 5'-CACCATGGAGTTGGGGCTGTGCTGG-3' (SEQ ID NO: 58); 25 VH3-53 sense, 5'-CACCATGGAGTTTTGGCTGAGCTGG-3' (SEQ ID NO: 59); VH3- 6 4 sense, 5'-CACCATGACGGAGTTTGGGCTGAGC-3' (SEQ ID NO: 60); or VH1 6 sense, 5'-CACCATGTCTGTCTCCTTCCTCATCTT-3' (SEQ ID NO: 61); and VH3 anti-sense - IgM ASO, 5'-GTGCTGCTGATGTCAGAGTTG-3' (SEQ ID NO: 30). We gel purified and cloned the VH PCR products into the pCR1000 plasmid of the TA TM 30 cloning system (Invitrogen , San Diego, CA) according to the manufacturer's instructions. We isolated the plasmid DNA using the Maxi plasmid protocol (Qiagen Inc., Chatsworth, CA) and sequenced using the ABI-PRISM Big Dye terminator cycle sequencing ready reaction kit (Perkin Elmer, Torrance, CA). We compared the variable- WO 2004/099251 PCT/US2004/014276 37 region sequences to the database of human immunoglobulin sequences using DNA PLOT (V Base Index; M7RC Center for Protein Engineering, Cambridge, United Kingdom; Mukherjee et al., J. Exp. Med. 177:1105-16 (1993)) to determine the gene usage and to identify the CDR1, CDR2 and CDR3 sequences. 5 WO 2004/099251 PCT/US2004/014276 38 Table 4: Nucleic Acid Sequences of Heavy Chains of Mabs G14F7E5, G15B4G5 and G19B9G7. Identity of Nucleic Acid Sequence SEQ ID NO: Sequence G14F7E5 5'- GAAGATCTCA CCATGTCTGT CTCCTTCCTC 31 variable ATCTTCTTGC CCGTACTGGG CCTCCCATGG region GGTGTCCTGT CACAGGTACA GCTGCAGCAG TCAGGTCCAG GACTGGTGAA GCCCTCGCAG ACCCTCTCAC TCACCTGTGC CATCTCCGGG GACAGTGTCT CTAGCAACAA TGCTGCTTGG AACTGGATCA GGCAGTCCCC ATCGAGAGGC CTTGAGTGGC TGGGAAGGAC ATACTTCAGG TCCAAGTGGT ATAATGATTA TGCAGTATCT GTGAAAAGTC GAATAACCAT CAACCCAGAC ACATCCAAGA ACCAGTTCTC CCTGCAGCTG AACTCTGTGA CTCCCGAGGA CACGGCTGTG TATTACTGTG CTAGAGAGGG TACTATGATT CGGGGAATTA TAAACTGGTT CGACTCCTGG GGCCAGGGAA CCCTGGTCAC CGTCTCCTCA GGGAGTGCAT CCGCCCCAAC CCTTTTCCCC CTCGT -3' G14F7E5 5'- GGGGACAGTG TCTCTAGCAA CAATGCTGCT 32 CDR1 TGGAAC -3' G14F7E5 5'- AGGACATACT TCAGGTCCAA GTGGTATAAT 33 CDR2 GATTATGCAG TATCTGTGAA AAGT -3' G14F7E5 5'- GAGGGTACTA TGATTCGGGG AATTATAAAC 34 CDR3 TGGTTCGACT CC -3' G15B4G5 5'- CTGAGCTGGT TTCCTGTTGC TATTTTTAAA 35 variable GGTGTCCAGT GTGAGGTGCA GCTGGTGGAG region TCTGGGGAAG GCTTGGTCCA GCCTGGGGGG TCCCTGAGAC TCTCCTGTGC AGCCTCTGGA TTCACCTTCA GTAGCTATGC TATGCACTGG GTCCGCCAGG CTCCAGGGAA GGGACTGGAA TATGTTTCAG CTATTAGTAG TAATGGGGGT AGCACATATT ATGCAGACTC TGTGAAGGGC AGATTCACCA TCTCCAGAGA CAATTCCAAG AACACGCTGT ATCTTCAAAT GGGCAGCCTG AGAGCTGAGG ACATGGCTGT GTATTACTGT GCGAGAGATC ATACGATATT TGGACTGGTT CCTCCGTTGG ACTACTGGGG CCAGGGAACC CTGGTCACCG TCTCCTCAGG GAGTGCATCC GCCCCAACCC TTTTCCCCCT CGTCTCCTGT GAGAATTCCC CGTCGGATAC GAGCAGCGTG GCCGTTGGCT GCCTCGCACA GGACTTCCTT CCCGACTCCA TCACTTTCTC CTGGAAATAC AAGAACAACT CTGAC-3' G15B4G5 5'- GGATTCACCT TCAGTAGCTA TGCTATGCAC -3' 36 CDR1 WO 2004/099251 PCT/US2004/014276 39 Identity of Nucleic Acid Sequence SEQ ID NO: Sequence G15B4G5 5'- GCTATTAGTA GTAATGGGGG TAGCACATAT 37 CDR2 TATGCAGACT CTGTGAAGGG C -3' G15B4G5 5'- GATCATACGA TATTTGGACT GGTTCCTCCG 38 CDR3 TTGGACTAC -3' G19B9G7 5'- ATGTCTGTCT CCTTCCTCAT CTTCTTGCCC 39 variable GTGCTGGGCC TCCCATGGGG TGTCCTGTCA region CAGGTACAGC TGCAGCAGTC AGGTCCAGGA CTGGTGAAGC CCTCGCAGAC CCTCTCACTC ACCTGTGCCA TCTCCGGGGA CAGTGTCTCT AGCAACAATG CTGCTTGGAA CTGGATCAGG CAGTCCCCAT CGAGAGGCCT TGAGTGGCTG GGAAGGACAT ACTACAGGTC CTACTGGTAT AATGATTATG CAGTATCTGT GAAAAGTCGA ATAACCATCA ACCCAGACAC ATCCAAGAAC CAGTTCTCCC TGCAGCTGAA CTCTGTGACT CCCGAGGACA CGGCTGTGTA TTACTGTGCA AGAGAGGGTA CTATGATTCG GGGAATTATA AACTGGTTCG ACTCCTGGGG CCAGGGAACC CTGGTCACCG TCTCCTCAGG GAGTGCATCC GCCCCAACCC-3' G19B9G7 5'- GGGGACAGTG TCTCTAGCAA CAATGCTGCT 40 CDR1 TGGAA C -3' G19B9G7 5'- AGGACATACT ACAGGTCCTA CTGGTATAAT 41 CDR2 GATTATGCAG TATCTGTGAA AAGT -3' G19B9G7 5'- GAGGGTACTA TGATTCGGGG AATTATAAAC 42 CDR3 TGGTTCGACT CC -3' WO 2004/099251 PCT/US2004/014276 40 Table 5: Amino Acid Sequences of Heavy Chains of Mabs G14F7E5, G15B4G5 and G19B9G7. Identity of Amino Acid Sequence SEQ ID NO: Sequence G14F7E5 EDLTMSVSFL IFLPVLGLPW GVLSQVQLQQ 43 variable SGPGLVKPSQ TLSLTCAISG DSVSSNNAAW region NWIRQSPSRG LEWLGRTYFR SKWYNDYAVS VKSRITINPD TSKNQFSLQL NSVTPEDTAV YYCAREGTMI RGIINWFDSW GQGTLVTVSS GSASAPTLFP L G14F7E5 GDSVSSNNAA WN 44 CDR1 G14F7E5 RTYFRSKWYN DYAVSVKS 45 CDR2 G14F7E5 EGTMIRGIlN WFDS 46 CDR3 G15B4G5 LSWFPVAIFK GVQCEVQLVE SGEGLVQPGG 47 variable SLRLSCAASG FTFSSYAMHW VRQAPGKGLE region YVSAISSNGG STYYADSVKG RFTISRDNSK NTLYLQMGSL RAEDMAVYYC ARDHTIFGLV PPLDYWGQGT LVTVSSGSAS APTLFPLVSC ENSPSDTSSV AVGCLAQDFL PDSITFSWKY KNNSD G15B4G5 GFTFSSYAMH 48 CDR1 G15B4G5 AISSNGGSTY YADSVKG 49 CDR2 G15B4G5 DHTIFGLVPP LDY 50 CDR3 G19B9G7 MSVSFLIFLP VLGLPWGVLS QVQLQQSGPG 51 variable LVKPSQTLSL TCAISGDSVS SNNAAWNWIR region QSPSRGLEWL GRTYYRSYWY NDYAVSVKSR ITINPDTSKN QFSLQLNSVT PEDTAVYYCA REGTMTRGII NWFDSWGQGT LVTVSSGSAS APT G19B9G7 GDSVSSNNAA WN 52 CDR1 G19B9G7 RTYYRSYWYN DYAVSVKS 53 CDR2 G19B9G7 EGTMIRGIIN WFDS 54 CDR3 The bolded sequences are signal (leader) sequences. 5 [0139] Analysis of the heavy chain sequence revealed that G15B4G5 comprises the germline sequence of a human VH 3-64 gene. The variable domain of G15B4G5 further utilizes a human D3-9 gene and a human JH4b gene. A comparison of the variable domain sequences of G15B4G5, which confers protection against C. neoformans infection WO 2004/099251 PCT/US2004/014276 41 and another human anti-C. neoformans GXM which has been said to confer protection shows conserved residues in the CDR2. See Fig. 3. [01401 Example 5 - Mouse Protection Experiments 5 [01411 The protective efficacy of the MAbs was evaluated in passive protection experiments in mice. Each MAb or the control myeloma IgM was diluted in sterile PBS and 1000, 100, 50, 5 and 0.5 tg doses were administered intraperitoneally (IP) to each of ten 6-8 week old female BALB/c mice (obtained from NCI) one hour prior to IP infection 10 with 5x10 6 colony-forming-units (cfu) of C. neoformans strain 24067. The injections were 0.1 ml, diluted in PBS, and the fungal inoculum was confirmed by plating on saboraud dextrose agar plates (Fisher). The number of surviving mice was monitored daily. When the control mice died, survival was evaluated statistically with the Kaplan Meier log-rank survival test. A 100 tg dose of G15B4G5 was protective. No other dose 15 or MAb conferred protection that was greater than that for the controls. GI 9B9G7 enhanced lethality (relative to PBS) at all concentrations. The results of this experiment are shown in Figure 2. [0142] Throughout this specification and claims, the word "comprise," or variations 20 such as "comprises" or "comprising" will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers. [0143] All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Although the 25 foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

Claims (43)

1. A monoclonal antibody or an antigen-binding portion thereof that specifically binds the capsular polysaccharide glucuronoxylomannan 5 (GXM) of Cryptococcus neoformans, Wherein said antibody or portion comprises: (a) a heavy chain amino acid sequence comprising CDR1, CDR2 and CDR3 amino sequences of a human VH 3-64 gene or a human VH-6-1 gene, with or without a signal sequence; 10 (b) a light chain amino acid sequence comprising CDR1, CDR2 and CDR3 amino sequences of a human VK A27 gene, with or without a signal sequence; or (c) both (a) and (b), wherein said amino acid sequence may comprise up to 6 mutations from 15 the germline gene sequence.

2. The antibody or antigen binding portion according to claim 1, wherein the amino acid sequences are the germline gene sequences. 20

3. The antibody or antigen-binding portion according to claim 1, wherein the antibody comprises heavy chain and light chain CDRI, CDR2 and CDR3 sequences selected from the group consisting of: (a) the heavy chain CDRI, CDR2 and CDR3 amino acid sequences of SEQ ID NO: 43 and the light chain CDR1, CDR2 and CDR3 amino acid 25 sequences of SEQ ID NO: 1; (b) the heavy chain CDR 1, CDR2 and CDR3 amino acid sequences of SEQ ID NO: 47 and the light chain CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO: 5; and (c) the heavy chain CDRI, CDR2 and CDR3 amino acid sequences of SEQ 30 ID NO: 51 and the light chain CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:9.

4. The antibody or antigen-binding portion according to claim 1, wherein the antibody comprises a heavy chain and a light chain, and wherein the amino WO 2004/099251 PCT/US2004/014276 43 acid sequences of the heavy chain and light chain are selected from the group consisting of: (a) the amino acid sequence of the heavy chain and the amino acid sequence of the light chain of antibody G14F7E5, with or without signal 5 sequences; (b) the amino acid sequence of the heavy chain and the amino acid sequence of the light chain of antibody G15B4G5 with or without signal sequences; and (c) the amino acid sequence of the heavy chain and the amino acid 10 sequence of the light chain of antibody G19B9G7 with or without signal sequences.

5. The antibody or antigen-binding portion according to claim 1, wherein the heavy chain and the light chain comprise a heavy chain variable domain 15 and alight chain variable domain, respectively, selected from the group consisting of: (a) the heavy chain variable domain of SEQ ID NO: 43 and the light chain variable domain of SEQ ID NO: 1, with or without the signal sequence; 20 (b) the heavy chain variable domain of SEQ ID NO: 47 and the light chain variable domain of SEQ ID NO: 5, with or without the signal sequence; and (c) the heavy chain variable domain of SEQ ID NO: 51 and the light chain variable domain of SEQ ID NO: 9, with or without the signal 25 sequence.

6. A cell line selected from the group consisting of G14F7E5 (ATCC Accession No. PTA-5170), G15B4G5 (ATCC Accession No. PTA-5171) or G19B9G7 (ATCC Accession No. PTA-5172). 30

7. A monoclonal antibody produced by the cell line according to claim 6. WO 2004/099251 PCT/US2004/014276 44

8. A monoclonal antibody that specifically binds C. neoformans GXM wherein the antibody comprises the heavy chain and light chain amino acid sequence of the monoclonal antibody according to claim 7. 5

9. An isolated antibody that specifically binds C. neoformans GXM, wherein the light chain of said antibody utilizes a human VKIII DPK22/A27 gene.

10. The antibody according to claim 6, wherein the light chain further utilizes a human J,1 gene. 10

11. An isolated antibody that specifically binds C. neoformans GXM, wherein the heavy chain of said antibody utilizes a human VH 3-64 or a human VH 6-1 gene. 15

12. An antibody or an antigen-binding portion thereof that specifically binds the capsular polysaccharide glucuronoxylomannan (GXM) of Cryptococcus neoformans, wherein said antibody or portion comprises a light chain, said light chain amino acid sequence comprising an amino acid sequence selected from the group consisting of: 20 (a) the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 13; (b) the amino acid sequence of residues 1 to 99, inclusive, of the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 13; (c) the amino acid sequence of residues 16 to 89, inclusive, of the 25 amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 13; and (d) the CDR1, CDR2 and CDR3 amino acid sequences encoded by the DNA sequences set forth in SEQ ID NOs: 14, 15 and 16. 30

13. A nucleic acid molecule comprising a nucleotide sequence encoding an amino acid sequence selected from the group consisting of: (a) the amino acid sequence set forth in SEQ ID NO: 1; WO 2004/099251 PCT/US2004/014276 45 (b) the amino acid sequence of residues 1 to 99, inclusive of the amino acid sequence set forth in SEQ ID NO: 1; (c) the amino acid sequence of residues 16 to 89, inclusive, of the amino acid sequence set forth in SEQ ID NO: 1; and 5 (d) the CDRI, CDR2 and CDR3 amino acid sequences set forth in SEQ ID NOs: 2, 3 and 4.

14. A polypeptide comprising an amino acid sequence selected from the group consisting of: 10 (a) the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 13; (b) the amino acid sequence of residues I to 99, inclusive, of the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 13; (c) the amino acid sequence of residues 16 to 89, inclusive, of the 15 amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 13; and (d) the CDRI, CDR2 and CDR3 amino acid sequences encoded by the DNA sequences set forth in SEQ ID NOs: 14, 15 and 16. 20

15. A nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of: (a) the sequence set forth in SEQ ID NO: 13; (b) the nucleotide sequence of positions 1 to 297 of SEQ ID NO: 13; (c) the CDR1-CDR3 encoding sequence of SEQ ID NO:13; and 25 (d) the CDR1, CDR2 and CDR3 encoding sequences of SEQ ID NOs: 14, 15 and 16.

16. An antibody or an antigen-binding fragment thereof that specifically binds the capsular polysaccharide glucuronoxylomannan (GXM) of Cryptococcus 30 neoformans, wherein said antibody or fragment comprises a light chain comprising an amino acid sequence selected from the group consisting of: (a) the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO:

17; WO 2004/099251 PCT/US2004/014276 46 (b) the amino acid sequence of residues I to 102, inclusive, of the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 17; (c) the amino acid sequence of residues 19 to 92, inclusive, of the 5 amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 17; and (d) the CDRI, CDR2 and CDR3 amino acid sequences encoded by the DNA sequences set forth in SEQ ID NOs: 18, 19 and 20. 10 17. A polypeptide comprising an amino acid sequence selected from the group consisting of: (a) the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 17; (b) the amino acid sequence of residues 1 to 102, inclusive, of the 15 amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 17; (c) the amino acid sequence of residues 19 to 92, inclusive, of the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 17; and 20 (d) the CDR1, CDR2 and CDR3 amino acid sequences encoded by the DNA sequences set forth in SEQ ID NOs: 18, 19 and 20.

18. A nucleic acid molecule comprising a nucleotide sequence encoding an amino acid sequence selected from the group consisting of: 25 (a) the amino acid sequence encoded set forth in SEQ ID NO: 5; (b) the amino acid sequence of residues 1 to 102, inclusive, of the amino acid sequence set forth in SEQ ID NO: 5; (c) the amino acid sequence of residues 19 to 92, inclusive, of the amino acid sequence set forth in SEQ ID NO: 5; and 30 (d) the CDRI, CDR2 and CDR3 amino acid sequences set forth in SEQ ID NOs: 6, 7 and 8.

19. A nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of: WO 2004/099251 PCT/US2004/014276 47 (a) the DNA sequence set forth in SEQ ID NO: 17; (b) the nucleotide sequence of positions I to 306 of SEQ ID NO: 17; (c) the CDR1-CDR3 encoding DNA sequence of SEQ ID NO: 17; and (d) the CDR1, CDR2 and CDR3 encoding DNA sequences of SEQ ID 5 NOs: 18, 19 and 20.

20. An antibody or an antigen-binding fragment thereof that specifically binds the capsular polysaccharide glucuronoxylomannan (GXM) of Cryptococcus neoformans, wherein said antibody or fragment comprises a light chain 10 amino acid sequence comprising an amino acid sequence selected from the group consisting of: (a) the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 21; (b) the amino acid sequence of residues 1 to 96, inclusive, of the amino 15 acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 21; (c) the amino acid sequence of residues 13 to 86, inclusive, of the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 21; and (d) the CDR1, CDR2 and CDR3 amino acid sequences encoded by the 20 DNA sequences set forth in SEQ ID NOs: 22, 23 and 24.

21. A polypeptide comprising an amino acid sequence selected from the group consisting of: (a) the amino acid sequence encoded by the DNA sequence set forth in 25 SEQ ID NO: 21; (b) the amino acid sequence of residues 1 to 96, inclusive, of the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 21; (c) the amino acid sequence of residues 13 to 86, inclusive, of the amino acid sequence encoded by the DNA sequence set forth in SEQ ID 30 NO: 21; and (d) the CDR1, CDR2 and CDR3 amino acid sequences encoded by the DNA sequences set forth in SEQ ID NOs: 22, 23 and 24. WO 2004/099251 PCT/US2004/014276 48

22. A nucleic acid molecule comprising a nucleotide sequence encoding an amino acid sequence selected from the group consisting of: (a) the amino acid sequence set forth in SEQ ID NO: 9; (b) the amino acid sequence of residues 1 to 96, inclusive, of the amino 5 acid sequence set forth in SEQ ID NO: 21; (c) the amino acid sequence of residues 13 to 86, inclusive, of the amino acid sequence set forth in SEQ ID NO: 9; and (d) the CDR1, CDR2 and CDR3 amino acid sequences set forth in SEQ ID NOs: 10, 11 and 12. 10

23. A nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of: (a) the DNA sequence set forth in SEQ ID NO: 21; (b) the nucleotide sequence of positions 1 to 288 of SEQ ID NO: 21; 15 (c) the CDR1-CDR3 encoding DNA sequence of SEQ ID NO: 21; and (d) the CDR1, CDR2 and CDR3 encoding DNA sequences of SEQ ID NOs: 22, 23 and 24.

24. An antibody or an antigen-binding portion thereof that specifically binds 20 the capsular polysaccharide glucuronoxylomannan (GXM) of Cryptococcus neoformans, wherein said antibody or portion comprises a light chain, said light chain amino acid sequence comprising an amino acid sequence selected from the group consisting of: (a) the amino acid sequence encoded by the DNA sequence set forth in 25 SEQ ID NO: 31, 35 or 39; (b) the amino acid sequence of residues I to 150, inclusive, of the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 31; residues 1-136, inclusive, of the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 35; or residues 1 to 146, 30 inclusive, of the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 39; (c) the amino acid sequence of residues 50 to 139, inclusive, of the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 31; the amino acid sequence of residues 40 to 125, inclusive, of the WO 2004/099251 PCT/US2004/014276 49 amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 35; the amino acid sequence of residues 46 to 135, inclusive, of the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 39; and 5 (d) the CDR1, CDR2 and CDR3 amino acid sequences encoded by the DNA sequences set forth in SEQ ID NOs: 32, 33 and 34; 36, 37 and 38 or 40, 41 and 42.

25. A nucleic acid molecule comprising a nucleotide sequence encoding an 10 amino acid sequence selected from the group consisting of: (a) the amino acid sequence set forth in SEQ ID NO: 43, 47 or 51; (b) the amino acid sequence of residues I to 150, inclusive of the amino acid sequence set forth in SEQ ID NO: 43; residues 1-136, inclusive, of the amino acid sequence encoded by the DNA sequence set forth in SEQ ID 15 NO: 35; or residues 1 to 146, inclusive, of the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 39; (c) the amino acid sequence of residues 50 to 139, inclusive, of the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 31; the amino acid sequence of residues 40 to 125, inclusive, of the 20 amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 35; the amino acid sequence of residues 46 to 135, inclusive, of the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 39; and (d) the CDR1, CDR2 and CDR3 amino acid sequences encoded by the 25 DNA sequences set forth in SEQ ID NOs: 32, 33 and 34; 36, 37 and 38 or 40, 41 and 42.

26. A polypeptide comprising an amino acid sequence selected from the group consisting of: 30 (a) the amino acid sequence set forth in SEQ ID NO: 43, 47 or 51; (b) the amino acid sequence of residues I to 150, inclusive of the amino acid sequence set forth in SEQ ID NO: 43; residues 1-136, inclusive, of the amino acid sequence encoded by the DNA sequence set forth in SEQ ID WO 2004/099251 PCT/US2004/014276 50 NO: 35; or residues 1 to 146, inclusive, of the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 39; (c) the amino acid sequence of residues 50 to 139, inclusive, of the amino acid sequence encoded by the DNA sequence set forth in SEQ ID 5 NO: 31; the amino acid sequence of residues 40 to 125, inclusive, of the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 35; the amino acid sequence of residues 46 to 135, inclusive; of the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 39; and 10 (d) the CDR1, CDR2 and CDR3 amino acid sequences encoded by the DNA sequences set forth in SEQ ID NOs: 32, 33 and 34; 36, 37 and 38 or 40, 41 and 42.

27. The nucleic acid molecule according to any one of claims 13, 15, 18, 19, 15 22, 23 and 25, operably linked to an expression control sequence.

28. A host cell transformed with a nucleic acid molecule according to claim 27.

29. A method for producing an antibody or an antigen binding fragment thereof 20 that specifically binds C. neoformans GXM, comprising the step of culturing a host cell according to claim 28.

30. A host cell transformed with a nucleic acid molecule according to any one of claims 13, 15, 18, 19, 22, 23 and 25. 25

31. A method for producing an antibody or an antigen binding fragment thereof that specifically binds C. neoformans GXM, comprising the step of culturing a host cell according to claim 30. 30

32. A composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 1-5, 7-12, 16, 20 and 24, and a pharmaceutically acceptable carrier. WO 2004/099251 PCT/US2004/014276 51

33. The composition according to claim 32, further comprising a component selected from the group consisting of: (a) a diagnostic agent; and (b) a therapeutic agent. 5

34. A kit comprising the antibody or antigen-binding fragment thereof according to any one of claims 1-5, 7-12, 16, 20 and 24.

35. A method for preventing or reducing the severity of conditions or disorders 10 caused by C. neoformans infection in a subject in need thereof comprising the step of administering an effective amount of the antibody or antigen binding fragment thereof according to any one of claims 1-5, 7-12, 16, 20 and 24 or a composition according to any one of claims 32 or 33. 15

36. A method for increasing the resistance of a subject in need thereof to infection by C. neoformans or to conditions or disorders caused by such infection, comprising the step of administering the antibody or antigen binding fragment thereof according to according to any one of claims 1-5, 7-12, 16, 20 and 24 or a composition according to any one of claims 32 or 20 33.

37. The method according to claim 35 or 36, wherein the subject is immunocompromised. 25

38. The method according to claim 35 or 36, wherein the subject is infected with HIV-1.

39. The method according to claim 35 or 36 wherein the subject lacks one or more human VH 3 family genes. 30

40. The method according to any one of claims 35-39, wherein the anti-C. neoformans GXM antibody or antigen-binding fragment thereof is administered in conjunction with the administration of another therapeutic agent. WO 2004/099251 PCT/US2004/014276 52

41. A method for detecting C. neoformans infection comprising contacting a sample from a subject suspected of being infected with an antibody or antigen-binding fragment according to any one of claims 1-5, 7-12, 16, 20 5 and 24 and detecting the binding of said antibody or fragment to C. neoformans GXM.

42. The antibody or antigen-binding portion according to any one of claims 1 5, 7-12, 16, 20 and 24 which is derived from a non-human transgenic 10 animal.

43. The antibody or antigen-binding portion according to claim 42, wherein the non-human transgenic animal is a XenoMouse@ animal. 15